Status and phase
Conditions
Treatments
About
Diclophenac potassium and ceftazidime are commercially available drugs that are used in various clinical situations. They are safe and known for years. Diclophenac potassium and Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is currently standard treatment for prevention of (PEP) while ceftazidime is possible alternative treatment for patients with contraindications for nonsteroidal medicines. The aim of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP.
Full description
Study type:
Interventional Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: only Investigator Primary Purpose: Prevention Study Phase: Phase 4
Conditions or Focus of the study: Post ERCP pancreatitis
Intervention information
Intervention Names ERCP
Arm Information
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
o Unwillingness or inability to consent for the study
Primary purpose
Allocation
Interventional model
Masking
124 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal